Skip to main content
. 2011 Sep;20(121):201–207. doi: 10.1183/09059180.00002011

Figure 5.

Figure 5.

Exploratory pooled analysis (studies 004 and 006 combined) of change in forced vital capacity (FVC) with pirfenidone 2,403 mg·day−1 (□: n = 345) or placebo (▪: n = 347) in patients with idiopathic pulmonary fibrosis [29, 35]. #: p = 0.005, rank ANCOVA (pirfenidone 2,403 mg·day−1 versus placebo at week 72).